市场趋势 - 股市持续上涨并收复自特朗普关税宣布以来的跌幅 [1] - 大盘股在市场中占据主导地位 [1] 分析师背景 - 分析师在华尔街和硅谷有覆盖科技公司的经验 [1] - 分析师担任多家种子轮初创公司的外部顾问 [1] - 分析师自2017年起定期为Seeking Alpha撰稿 [1] - 分析师的评论被多家网络媒体引用 [1] - 分析师的文章被同步到Robinhood等流行交易应用的公司页面 [1]

JP Morgan analyst Lisa C. Gill revised her 2025 outlook on GoodRx Holdings GDRX following the company’s first-quarter earnings. Gill reaffirmed an Overweight rating on the stock and maintained her $7 price forecast.The company reported first-quarter 2025 revenue of $203 million (above the $202.21 million estimate), up 3% year-over-year. Adjusted EBITDA rose to $69.8 million, with margins improving to 34.4% from 31.7%. Net income came in at $11.1 million, reversing a $1 million loss in the prior year.Pharma ...

Investors looking for stocks in the Medical Services sector might want to consider either GoodRx Holdings, Inc. (GDRX) or Progyny (PGNY) . But which of these two stocks is more attractive to value investors? We'll need to take a closer look to find out.Everyone has their own methods for finding great value opportunities, but our model includes pairing an impressive grade in the Value category of our Style Scores system with a strong Zacks Rank. The proven Zacks Rank emphasizes companies with positive estima ...

While the proven Zacks Rank places an emphasis on earnings estimates and estimate revisions to find strong stocks, we also know that investors tend to develop their own individual strategies. With this in mind, we are always looking at value, growth, and momentum trends to discover great companies.Looking at the history of these trends, perhaps none is more beloved than value investing. This strategy simply looks to identify companies that are being undervalued by the broader market. Value investors use a v ...

GoodRx (GDRX) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Company Participants Aubrey Reynolds - Director & Head - Investor RelationsWendy Barnes - President & CEOChris McGinnis - CFOLisa Gill - Managing DirectorJohn Ransom - Managing Director, Director of Healthcare ResearchCharles Rhyee - Managing DirectorJailendra Singh - Managing Director Conference Call Participants Craig Hettenbach - AnalystGeorge Hill - AnalystSteven Valiquette - MD & Senior Equity Research Analyst - Covering Health Care Technolog ...

GoodRx (GDRX) Q1 2025 Earnings Call May 08, 2025 08:00 AM ET Speaker0 Ladies and gentlemen, thank you for standing by, and welcome to the GoodRx First Quarter twenty twenty five Earnings Call. As a reminder, today's conference is being recorded. I would now like to introduce your host for today's call, Aubrey Reynolds, Director of Investor Relations. Ms. Reynolds, you may begin. Speaker1 Thank you, operator. Good morning, everyone, and welcome to GoodRx's earnings conference call for the first quarter twent ...

As these metrics influence top- and bottom-line performance, comparing them to the year-ago numbers and what analysts estimated helps investors project a stock's price performance more accurately. GoodRx Holdings, Inc. (GDRX) reported $202.97 million in revenue for the quarter ended March 2025, representing a year-over-year increase of 2.6%. EPS of $0.09 for the same period compares to $0.08 a year ago. The reported revenue compares to the Zacks Consensus Estimate of $202.59 million, representing a surprise ...

GoodRx Holdings, Inc. (GDRX) came out with quarterly earnings of $0.09 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.08 per share a year ago. These figures are adjusted for non-recurring items.A quarter ago, it was expected that this company would post earnings of $0.09 per share when it actually produced earnings of $0.09, delivering no surprise.Over the last four quarters, the company has not been able to surpass consensus EPS estimates.GoodRx, which belongs to the ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 ________________________________ FORM 10-Q ________________________________ (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to ______. Commission File Number: 001-39549 ________________________ ...

"Since stepping into this role, I have dedicated my time strengthening our leadership team, gaining a deeper understanding of our business, meeting with key partners, understanding the macroeconomic environment, and identifying key capabilities and growth opportunities," said Wendy Barnes, Chief Executive Officer and President of GoodRx. "I can confidently say that we are in a very strong position to deliver meaningful value across the pharmacy ecosystem. Furthermore, we are focused on high-impact initiativ ...